Showing 6251-6260 of 7385 results for "".
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a
- The National Eczema Association Names Amy Fauver New VP For Advocacy & Accesshttps://practicaldermatology.com/news/the-national-eczema-association-names-amy-fauver-new-vp-for-advocacy-access/2458872/The National Eczema Association (NEA) named Amy Fauver as Vice President for Advocacy and Access. The NEA says in this new position, Ms. Fauver will build its advocacy capacity and better leverage the voices of the eczema community, enhancing NEA’s ability to create meaningful changes in ec
- AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumabhttps://practicaldermatology.com/news/astrazeneca-and-valeant-pharmaceuticals-to-partner-on-brodalumab/2458881/AstraZeneca and Valeant Pharmaceuticals International, Inc. entered into a collaboration agreement under which AstraZeneca will grant Valeant an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody that is in development for patients with moderate
- ASDS/ASDSA Accepts 'Call to Action' on Skin Cancer Preventionhttps://practicaldermatology.com/news/asdsasdsa-accepts-call-to-action-on-skin-cancer-prevention/2458883/The American Society for Dermatologic Surgery (ASDS) announced it actively supports the measures to fight skin cancer set forth in the Skin Cancer Prevention Progress Report that was recently issued by the Centers for Disease Control and Prevention. The Progress Report builds upon last su
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- DermTube Kicks Off Video Coverage of SAAD in New Yorkhttps://practicaldermatology.com/news/dermtube-kicks-off-video-coverage-of-saad-in-new-york/2458889/With the American Academy of Dermatology meeting currently underway in New York, Practical Dermatology® magazine and DermTube have begun their joint video coverage of the event, with video interview with key opinion leaders. Su
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) c